(Q34106497)

31 July 2017

1 reference

title

Serotoninergic neuroenteric modulators (English)

1 reference

31 July 2017

N J Talley

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

358

1 reference

31 July 2017

issue

9298

1 reference

31 July 2017

page(s)

2061-2068

1 reference

Irritable bowel syndrome: a technical review for practice guideline development

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Medical costs in community subjects with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

The impact of irritable bowel syndrome on health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Irritable bowel syndrome symptom patterns: frequency, duration, and severity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

The short-term natural history of irritable bowel syndrome: a time-series analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

EVIDENCE OF A GENETIC CONTRIBUTION TO FUNCTIONAL BOWEL DISORDER

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Psychometric scores and persistence of irritable bowel after infectious diarrhoea.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

The role of psychological and biological factors in postinfective gut dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Symptoms of irritable bowel syndrome in ulcerative colitis in remission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

The irritable bowel syndrome: long-term prognosis and the physician-patient interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Treatment of irritable bowel syndrome: a review of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

5-HT1D and 5-HT2B receptors mediate contraction of smooth muscle in human small intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Evidence for the involvement of a 5-HT4 receptor in the secretory response of human small intestine to 5-HT.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

A review of central 5-HT receptors and their function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

In vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: a segmental perfusion study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Effect of a 5HT3-antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Review article: tegaserod

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

1 reference

7 January 2021

The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Anxiolytic potential of 5-HT3 receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Gender differences in regional brain response to visceral pressure in IBS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Role of loperamide and placebo in management of irritable bowel syndrome (IBS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Ischemic colitis during treatment with alosetron

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Lotronex and the FDA: a fatal erosion of integrity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

5-HT3 and 5-HT4 receptor-mediated facilitation of the emptying phase of the peristaltic reflex in the marmoset isolated ileum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

5-HT(4) receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Characterization of the 5-hydroxytryptamine receptor type involved in inhibition of spontaneous activity of human isolated colonic circular muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Human colonic mucosa possesses a mixed population of 5-HT receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

1 reference

7 January 2021

Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Colonic mass movements in idiopathic chronic constipation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Effects of a serotonin 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Functional evidence for a 5‐HT2B receptor mediating contraction of longitudinal muscle in human small intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Evidence for 5-HT7 receptors mediating relaxation of human colonic circular smooth muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Misoprostol in the treatment of chronic refractory constipation: results of a long-term open label trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Towards identifying optimal doses for alpha-2 adrenergic modulation of colonic and rectal motor and sensory function.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Role of tachykinin NK2 receptors in normal and altered rectal sensitivity in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Peripheral actions of tachykinins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Possible site of action of TAK-637, a tachykinin NK(1) receptor antagonist, on the micturition reflex in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

Some of the challenges in drug development for irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

The impact of functional gastrointestinal disorders on quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2907103-3

7 January 2021

10.1016/S0140-6736(01)07103-3

Identifiers

DOI

1 reference

31 July 2017

1 reference